...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: let’s say Zen has been working towards

hummmmm,,,well,,if any of our molecules show credibility then an IPO will hopefully be arranged and application set in place,,the exchange should again be the NASDAQ of course,,,,,,we need a positive trial and or a buy out,,either one would work for me,,,,the sooner the better imo,,,, I am investor weary with both of DMcCs companies,,,,,yep,,,,they have been nothing short of dead weight in my accounts and what seems like forever,,,,,!

Share
New Message
Please login to post a reply